Bibliography
- Guerra CA, Snow RW, Hay SI. Mapping the global extent of malaria in 2005. Trends Parasitol 2006;22:353-8
- Snow RW, Guerra CA, Noor AM, et al. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 2006;434:214-7
- Rowe AK, Rowe SY, Snow RW, et al. The burden of malaria mortality among African children in the year 2000. Int J Epidemiol 2006;35:691-704
- WHO. WHO guidelines for the treatment of malaria. WHO/HTM/MAL/2006/1108. Geneva: World Health Organization, 2006
- Snow RW, Trape JF, Marsh K. The past, present and future of childhood malaria mortality in Africa. Trends Parasitol 2001;17:593-7
- O'Meara WP, Bejon P, Mwangi TW, et al. Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya. Lancet 2008;372:1555-62
- Ceesay SJ, Casals-Pascual C, Erskine J, et al. Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis. Lancet 2008;372:1545-54
- Talisuna AO, Bloland P, D'Alessandro U. History, dynamics, and public health importance of malaria parasite resistance. Clin Microbiol Rev 2004;17:235-54
- WHO Antimalarial Drug Combination Therapy. Report of a WHO technical consultation. Geneva: World Health Organization, 2001
- Attaran A, Barnes KI, Curtis C, et al. WHO, the Global Fund, and medical malpractice in malaria treatment. Lancet 2004;363:237-40
- Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg 2007;77(Suppl 6):181-92
- Bosman A, Mendis KN. A major transition in malaria treatment: the adoption and deployment of artemisinin-based combination therapies. Am J Trop Med Hyg 2007;77(Suppl 6):193-7
- Bathurst I, Hentschel C. Medicines for malaria venture: sustaining antimalarial drug development. Trends Parasitol 2006;22:301-7
- Deen JL, von Seidlein L, Dondorp A. Therapy of uncomplicated malaria in children: a review of treatment principles, essential drugs and current recommendations. Trop Med Intl Health 2008;13:1-20
- White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 1997;41:1413-22
- White NJ, Antimalarial DRUG. J Clin Invest 2004; 113: 1084-1092
- Wernsdorfer WH. Coartemether (arteemether and lumefantrine): an oral antimalarial drug. Expert Rev Anti Infect Ther 2004;2:181-96
- Abdulla S, Sagara I, Borrmann S, et al. Efficacy and safety of artemether-lumefantrine dispersible tablet in African infants and children with uncomplicated malaria: a randomised, investigator-blinded, multi-centre comparison with the crushed commercial tablet. Lancet 2008;372:1819-27
- Ezzet F, Mull R, Karbwang J. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. Br J Clin Pharmacol 1998;46:553-61
- Ezzet F, Van Vugt M, Nosten F, et al. Pharmacokinetics and pharmacodynamics of lumefantrine (Benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother 2000;44:697-704
- Price RN, Uhlemann AC, van Vugt M, et al. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant plasmodium falciparum malaria. Clin Infect Dis 2006;42:1570-77
- Omari AAA, Gamble C, Garner P. Artemether-lumefantrine (four-dose regimen) for treating uncomplicated falciparum malaria. Cochrane Database Sys Rev 2006;(2):CD005965. doi:10.1002/14651858.CD005965
- Omari AAA, Gamble C, Garner P. Artemether-lumefantrine (six-dose regimen) for treating uncomplicated falciparummalaria. Cochrane Database Sys Rev 2005;(4):CD005564. doi: 10.1002/14651858.CD005564
- Fanello CI, Karema C, van Doren W, et al. A randomised trial to assess the safety and efficacy of artemether lumefantrine (Coartem) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwanda. Trans R Soc Trop Med Hyg 2007;101:344-350
- van Vugt M, Ezzet F, Nosten F, et al. No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine. Am J Trop Med Hyg 1999;61:964-7
- Piola P, Fogg C, Bajunirwe F, et al. Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial. Lancet 2005;365:1467-73
- Mutabingwa TK, Anthony D, Heller A, et al. Amodiaquine alone, amodiaquine-sulfadoxinepyrimethamine, amodiaquine artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet 2005;365:1474-80
- Checchi F, Piola P, Fogg C, et al. Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda. Malar J 2006;5:59
- Stepniewska K, White NJ. Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria. Malar J 2006;22:127
- Sisowath C, Stromberg J, Martensson A, et al. In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J Inf Dis 2005;191:1014-17
- Humphreys GS, Merinopoulos I, Ahmed J, et al. Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria. Antimicrob Agents Chemother 2007;51:991-7
- Hatton CS, Peto TE, Bunch C, et al. Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet 1986;1:411-4
- Neftel KA, Woodtly W, Schimd M, et al. Amodiaquine induced agranulocytosis and liver damage. Br Med J 1986;292:721-3
- Maggs JL, Tingle MD, Kitteringham NR, et al. Drug-protein conjugates–XIV Mechanisms of formation of protein-arylating intermediates from amodiaquine, a myelotoxin and hepatotoxin in man. Biochem Pharmacol 1988;37:303-11
- Harrison AC, Kitteringham NR, Clarke JB, et al. The mechanism of bioactivation and antigen formation of amodiaquine in the rat. Biochem Pharmacol 1992;43:1421-30
- Clarke JB, Maggs JL, Kitteringham NR, et al. Immunogenicity of amodiaquine in the rat. Int Arch Allergy Appl Immunol 1990;91:335-42
- Olliaro P, Mussano P. Amodiaquine for treating malaria. Cochrane Database Sys Rev 2003;(2):CD000016
- Gasasira AF, Kamya MR, Achan J, et al. High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. Clin Infect Dis 2008;46:985-91
- Adjuik M, Agnamey P, Babiker A, et al. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet 2002;359:1365-72
- Checchi F, Balkan S, Vonhm BT, et al. Efficacy of amodiaquine for uncomplicated Plasmodium falciparum malaria in Harper, Liberia. Trans R Soc Trop Med Hyg 2002;96:670-3
- Schellenberg D, Kahigwa E, Drakeley C, et al. The safety and efficacy of sulfadoxine-pyrimethamine, amodiaquine and their combination in the treatment of uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg 2002;67:17-23
- Ringwald P, Keundjian A, Same Ekobo A, et al. Chimiorésistance de P. falciparum en milieu urbain à Yaoundé, Cameroun. Part 2: evaluation de l'efficacité de l'amodiaquine et de l'association sulfadoxine-pyriméthamine pour le traitement de l'accès palustre simple à Plasmodium falciparum à Yaoundé, Cameroun. Trop Med Int Health 2000;5:620-7
- Zwang J, Olliaro PL, Nosten F, et al. Efficacy of artesunate-amodiaquine (ASAQ) for the treatment of uncomplicated falciparum malaria in sub-Saharan Africa: an individual patient data metanalysis (IPDM) in 3,455 patients. Abstract 1005. Abstract Book. American Society of Tropical Medicine and Hygiene. 56th Annual Meeting. 8 November 2007. Philadelphia, Pennsylvania, USA
- Fanello CI, Karema C, van Doren W, et al. Tolerability of amodiaquine and sulphadoxine pyrimethamine, alone or in combination for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan adults. Trop Med Int Health 2006;11:589-96
- Wongsrichanalai C, Thimasarn K, Sirichaisinthop J. Antimalarial drug combination policy: a caveat. Lancet 2000;355:2245-7
- Nosten F, van-Vugt M, Price R, et al. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 2000;356:297-302
- Bukirwa H, Orton L. Artesunate plus mefloquine versus mefloquine for treating uncomplicatedmalaria. Cochrane Database Sys Rev 2005;(4):CD004531
- Grande T, Bernasconi A, Erhart A, et al. A randomised controlled trial to assess the efficacy of dihydroartemisinin piperaquine for the treatment of uncomplicated falciparum malaria in Peru [electronic only]. PLoS One 2007;2(10):e1101
- Okoyeh JN, Lege-Oguntoye L, Ugbode RO, et al. Responses of multidrug-resistant Plasmodium falciparum parasites to mefloquine in Nigerian children. Trop Med Int Health 1997;2:319-24
- Hwang J, Bitarakwate E, Pai M, et al. Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for uncomplicated malaria: a systematic review. Trop Med Int Health 2006;11:789-99
- The East African Network for Monitoring Antimalarial Treatment (EANMAT) The efficacy of antimalarial monotherapies, sulphadoxine–pyrimethamine and amodiaquine in East Africa: implications for sub-regional policy. Trop Med Int Health 2003;8:860-7
- International Artemisinin Study Group. Artesunate combinations for treatment of malaria: meta-analysis. Lancet 2004;363:9-17
- von Seidlein L, Milligan P, Pinder M, et al. Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial. Lancet 2000;355:352-57
- Bukirwa H, Critchley J. Sulfadoxine-pyrimethamine plus artesunate versus sulfadoxine-pyrimethamine plus amodiaquine for treating uncomplicated malaria. Cochrane Database Sys Rev 2006;(1):CD004966. doi: 10.1002/14651858.CD004966.pub2
- Nahum A, Erhart A, Gazard D, et al. Adding artesunate to sulphadoxine-pyrimethamine greatly improves the treatment efficacy in children with uncomplicated falciparum malaria on the coast of Benin, West Africa. Malar J 2007;6:170
- Nahum A, Erhart A, Ahounou D, et al. Extended high efficacy of the combination sulphadoxine-pyrimethamine with artesunate in children with uncomplicated falciparum malaria on the Benin coast, West Africa. Malar J 2009;8:37
- Prudhomme O'Meara W, Smith DL, McKenzie FE. Potential Impact of Intermittent Preventive Treatment (IPT) on spread of drug-resistant malaria. PLoS Med 2006;3(5):e141
- Alexander N, Sutherland C, Roper C, et al. Modelling the impact of intermittent preventive treatment for malaria on selection pressure for drug resistance. Malar J 2007;6:9
- Biswas S, Escalante A, Chaiyaroj S, et al. Prevalence of point mutations in the dihydrofolate reductase and dihydrofolate synthetase genes of Plasmodium falciparum isolates from India and Thailand: a molecular epidemiological study. Trop Med Int Health 2000;10:773-43
- Triglia T, Cowman AF. Primary structure and expression of the dihydropteroate synthetase gene of Plasmodium falciparum. Proc Natl Acad Sci USA 1994;91:7149-53
- Brooks DR, Wang P, Read M, et al. Sequence variation of the dihydromethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance sulfadoxine. Eur J Biochem 1994;224:397-405
- Tinto H, Ouedraogo JB, Zongo I, et al. Sulfadoxine-pyrimethamine efficacy and selection of Plasmodium falciparum DHFR mutations in Burkina Faso before its introduction as intermittent preventive treatment for pregnant women. Am J Trop Med Hyg 2007;76:608-13
- Coulibaly SO. Relationship between the use of chloroquine and sulphadoxine-pyrimethamine in pregnancy and resistance of Plasmodium falciparum in Burkina Faso. PhD Thesis 2006. Faculty of Health Sciences, Centre for Medical Parasitology, University of Copenhagen, Denmark and DBL - Institute for Health Research and Development, Copenhagen, Denmark
- Garner P, Gülmezoglu AM. Drugs for preventing malaria in pregnant women. Cochrane Database Sys Rev 2006;(4):CD000169. doi: 10.1002/14651858.CD000169.pub2
- Thera MA, Sehdev PS, Coulibaly D, et al. Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease. J Infect Dis 2005;192:1823-9
- Malamba SS, Mermin J, Reingold A, et al. Effect of cotrimoxazole prophylaxis taken by human immunodeficiency virus (HIV)-infected persons on the selection of sulfadoxine-pyrimethamine-resistant malaria parasites among HIV-uninfected household members. Am J Trop Med Hyg 2006;75:375-80
- Laufer MK, Plowe CV. Cotrimoxazole prophylaxis and malaria in Africa: have the important questions been answered? Am J Trop Med Hyg 2006;75:373-4
- Ashley EA, Krudsood S, Phaiphun L, et al. Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. J Infect Dis 2004;190:1773-82
- Ashley EA, McGready R, Hutagalung R, et al. A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clin Infect Dis 2005;41:425-32
- Denis MB, Davis TM, Hewitt S, et al. Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria. Clin Infect Dis 2002;35:1469-76
- Myint HY, Ashley EA, Daya NPJ, et al. Efficacy and safety of dihydroartemisinin-piperaquine. Trans R Soc Trop Med Hyg 2007;101:858-66
- Karema C, Fanello CI, Van Overmeir C, et al. Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. Trans R Soc Trop Med Hyg 2006;100:1105-1111
- Smithuis F, Kyaw MK, Phe O, et al. Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet 2006;367:2075-85
- Kamya MR, Yeka A, Bukirwa H, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: A randomized trial. PLoS Clin Trials 2007;2(5):e20. doi: 10.1371/journal.pctr.0020020
- Yeka A, Dorsey G, Kamya MR, et al. Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS ONE 2008;3(6):e2390. doi:10.1371/journal.pone.0002390
- Zongo I, Dorsey G, Rouamba N, et al. Randomized comparison of Amodiaquine plus Sulfadoxine-Pyrimethamine, Artemether-Lumefantrine, and Dihydroartemisinin-Piperaquine for the treatment of uncomplicated plasmodium falciparum malaria in Burkina Faso. Clin Infect Dis 2007;45:1453-61
- Janssens B, van Herp M, Goubert L, et al. A randomized open study to assess the efficacy and tolerability of dihydroartemisinin–piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia. Trop Med Int Health 2007;12:251-9
- Ratcliff A, Siswantoro H, Kenangalem E, et al. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 2007;369:757-65
- Hasugian AR, Purba HLE, Kenangalem E, et al. Dihydroartemisinin-Piperaquine versus Artesunate-Amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant plasmodium falciparum and plasmodium vivax malaria. Clin Infect Dis 2007;44:1067-74
- Obonyo CO, Juma EA, Ogutu BR, et al. Amodiaquine combined with sulfadoxine/pyrimethamine versus artemisinin-based combinations for the treatment of uncomplicated falciparum malaria in Africa: a meta-analysis. Trans R Soc Trop Med Hyg 2007;101:117-26
- Bell DJ, Nyirongo SK, Mukaka M, et al. Sulfadoxine-pyrimethamine–based combinations for malaria: a randomised blinded trial to compare efficacy, safety and selection of resistance in Malawi. PLoS ONE 2008;3:e1578. doi:10.1371/journal.pone.0001578
- Kublin JG, Cortese JF, Njunju EM, et al. Reemergence of chloroquine-sensitive plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis 2003;187:1870-5
- Laufer MK, Thesing PC, Eddington ND, et al. Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med 2006;355:1959-66
- Rwagacondo CE, Karema C, Mugisha V, et al. Is amodiaquine failing in Rwanda? Efficacy of amodiaquine alone and combined with artesunate in children with uncomplicated malaria. Trop Med Int Health 2004;9:1091-8
- Fanello CI, Karema C, Ngamije D, et al. A randomised trial to assess the efficacy and safety of chlorproguanil/dapsone + artesunate for the treatment of uncomplicated Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg 2008;102:412-20
- Mendis K, Sina BJ, Marchesini P, Carter R. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 2001;64S:97-106
- Sattabongkot J, Yimamnuaychoke N, Leelauoomlipi S, et al. Establishment of a human hepatocyte line that supports in vitro development of the exo-erythrocitic stages of the malaria parasites Plasmodium falciparum and P. vivax. Am J Trop Med Hyg 2006;74:708-15
- Baird JK. Neglect of plasmodium vivax malaria. Trends Parasitol 2007;23:533-9
- Price RN, Tjitra E, Guerra CA, et al. Vivax Malaria: neglected and not benign. Am J Trop Med Hyg 2007;77(Suppl 6):79-87
- Sumawinata IW, Bernadeta, Leksana B, et al. Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. Am J Trop Med Hyg 2003;68:416-20
- Baird JK, Hoffman SL. Primaquine therapy for malaria. CID 2004;39:1336-45
- Goller JL, Jolley D, Ringwald P, Biggs BA. Regional differences in the responses of Plasmodium vivax malaria to primaquine as anti-relapse therapy. Am J Trop Med Hyg 2007;76:203-7
- Leslie T, Mayan I, Mohammed N, et al. A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of plasmodium vivax in Northwest Frontier Province, Pakistan. PLoS ONE 2008;3(8):e2861. doi:10.1371/journal.pone.0002861
- Krudsood S, Tangpukdee N, Wilairatana P, et al. High-dose primaquine regimens against relapse of plasmodium vivax malaria. Am J Trop Med Hyg 2008;78:736-40
- Silachamroon U, Krudsood S, Treeprasertsuk S, et al. Clinical trial of oral artesunate with or without high-dose primaquine for the treatment of vivax malaria in Thailand. Am J Trop Med Hyg 2003;69:14-8
- Maguire JD, Krisin, Marwoto H, et al. Mefloquine is highly efficacious against chloroquine-resistant plasmodium vivax malaria and plasmodium falciparum malaria in Papua, Indonesia. Clin Inf Dis 2006;42:1067-72
- Karunajeewa HA, Mueller I, Senn M, et al. A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med 2008;359:2545-57
- Leslie T, Mayan MI, Hasan MA, et al. Sulfadoxine-pyrimethamine, chlorproguanil-dapsone, or chloroquine for the treatment of plasmodium vivax malaria in Afghanistan and Pakistan: a randomized controlled trial. JAMA 2007;297:2201-9
- Kolaczinski K, Durrani N, Rahim S, et al. Sulfadoxine-pyrimethamine plus artesunate compared with chloroquine for the treatment of vivax malaria in areas co-endemic for Plasmodium falciparum and P. vivax: a randomised non-inferiority trial in eastern Afghanistan. Trans R Soc Trop Med Hyg 2007;101:1081-7
- Menéndez C, D'Alessandro U, ter Kuile FO. Reducing the burden of malaria in pregnancy by preventive strategies. Lancet Infect Dis 2007;7:126-35
- Desai M, ter Kuile FO, Nosten F, et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis 2007;7:93-104
- Poespoprodjo JR, Fobia W, Kenangalem E, et al. Adverse pregnancy outcomes in an area where multidrug-resistant plasmodium vivax and plasmodium falciparum infections are endemic. Clin Inf Dis 2008;46:1374-81
- Nosten F, McGready R, D'Alessandro U, et al. Antimalarial drugs in pregnancy: a review. Curr Drug Saf 2006;1:1-15
- Dellicour S, Hall S, Chandramohan D, et al. The safety of artemisinins during pregnancy: a pressing question. Malar J 2007;6:15
- Nosten F, McGready R, Mutabingwa T. Case management of malaria in pregnancy. Lancet Infect Dis 2007;7:118-25
- Villegas L, McGready R, Htway M, et al. Chloroquine prophylaxis against vivax malaria in pregnancy: a randomized, double-blind, placebo-controlled trial. Trop Med Int Health 2007;12:209-18
- Hewitt K, Steketee R, Mwapasa V, et al. Interactions between HIV and malaria in non-pregnant adults: evidence and implications. AIDS 2006;20:1993-2004
- ter Kuile FO, Parise ME, Verhoeff FH, et al. The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-Saharan Africa. Am J Trop Med Hyg 2004;71:41-54
- Whitworth J, Morgan D, Quigley M, et al. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet 2000;356:1051-6
- French N, Nakiyingi J, Lugada E, et al. Increasing rates of malarial fever with deteriorating immune status in HIV-1-infected Ugandan adults. AIDS 2001;15:899-906
- Patnaik P, Jere CS, Miller WC, et al. Effects of HIV-1 serostatus, HIV-1 RNA concentration, and CD4 cell count on the incidence of malaria infection in a cohort of adults in rural Malawi. J Infect Dis 2005;192:984-91
- Chalwe V, Van geertruyden JP, Mutale F, et al. HIV-1 infection increases the risk of severe malaria in semi-immune adults in Zambia. Emerg Infect Dis 2009;15:749-55
- Laufer MK, van Oosterhout JJG, Thesing PC, et al. Malaria treatment efficacy among people living with HIV: the role of host and parasite factors. Am J Trop Med Hyg 2007;77:627-32
- Van geertruyden JP, Mulenga M, Mwananyanda L, et al. HIV-1 immune suppression and antimalarial treatment outcome in Zambian adults with uncomplicated malaria. J Infect Dis 2006;194:917-25
- Van geertruyden JP, Menten J, Colebunders R, et al. The impact of HIV-1 on the malaria parasite biomass in adults in sub-Saharan Africa contributes to the emergence of antimalarial drug resistance. Malar J 2008;7:134
- Bell DJ, Molineux ME. Treatment of childhood plasmodium falciparum malaria: current challenges. Expert Rev Anti Infect Ther 2007;5:141-52
- Day N, Dondorp AM. The management of patients with severe malaria. Am J Trop Med Hyg 2007;77(Suppl 6):29-35
- Checkley AM, Whitty CJM. Artesunate, artemether or quinine in severe Plasmodium falciparum malaria? Expert Rev Anti Infect Ther 2007;5:199-204
- Hien TT, Davis TM, Chuong LV, et al. Comparative pharmacokinetics of intramuscular artesunate and artemether in patients with severe falciparum malaria. Antimicrob Agents Chemother 2004;48:4234-4239
- Artemether-Quinine Meta-analysis study group. A meta-analysis using individual patient data of trials comparing artemether with quinine in the treatment of severe falciparum malaria. Trans R Soc Trop Med Hyg 2001;95:637-50
- Dondorp A, Nosten F, Stepniewska K, et al. Artesunate versus quinine for the treatment of severe falciparum malaria: a randomized trial. Lancet 2005;366:717-25
- Schultz LJ, Steketee RW, Macheso A, et al. The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi. Am J Trop Med Hyg 1994;51:515-22
- Parise ME, Ayisi JG, Nahlen BL, et al. Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. Am J Trop Med Hyg 1998;59:813-22
- Shulman CE, Dorman EK, Cutts F, et al. Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial. Lancet 1999;353:632-36
- Verhoeff FH, Brabin BJ, Chimsuku L, et al. An evaluation of the effects of intermittent sulfadoxine-pyrimethamine treatment in pregnancy on parasite clearance and risk of low birthweight in rural Malawi. Ann Trop Med Parasitol 1998;92:141-50
- Ter Kuile FO, van Eijk AM, Filler SJ. Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review. JAMA 2007;297(23):2603-16
- Bulatao RA, Ross JA. Rating maternal and neonatal health services in developing countries. Bull World Health Organ 2002;80:721-7
- Hill J, Kazembe P. Reaching the Abuja target for intermittent preventive treatment of malaria in pregnancy in African women: a review of progress and operational challenges. Trop Med Int Health 2006;11:409-18
- Knippenberg R, Lawn JE, Darmstadt GL, et al. Systematic scaling up of neonatal care in countries. Lancet 2005;365:1087-98
- Myer L, Harrison A. Why do women seek antenatal care late? Perspectives from rural South Africa. J Midwifery Womens Health 2003;48:268-72
- Crawley J, Hill J, Yartey J, et al. From evidence to action? Challenges to policy change and programme delivery for malaria in pregnancy. Lancet Infect Dis 2007;7:145-55
- WHO: Global strategy plan 2005 – 2010. Geneva: WHO, 2005
- WHO: WHO Expert Committee on Malaria (Twentieth report). Geneva: WHO, 2000
- Gies S, Coulibaly SO, Ky C, et al. Community based promotional campaign to improve uptake of intermittent preventive antimalarial treatment in pregnancy in Burkina Faso. Am J Trop Med 2009;80:460–469
- Gies S, Coulibaly SO, Ouattara FT, et al. A community effectiveness trial of strategies promoting intermittent preventive treatment with sulphadoxine-pyrimethamine in pregnant women in rural Burkina Faso. Malar J 2008;7:180
- Greenwood B. Review: Intermittent preventive treatment–a new approach to the prevention of malaria in children in areas with seasonal malaria transmission. Trop Med Int Health 2006;11:983-91
- Grobusch MP, Egan A, Gosling RD, et al. Intermittent preventive therapy for malaria: progress and future directions. Curr Opin Infect Dis 2007;20:613-20
- Meremikwu MM, Donegan S, Esu E. Chemoprophylaxis and intermittent treatment for preventing malaria in children. Cochrane Database Sys Rev 2008;(2):CD003756. doi: 10.1002/14651858.CD003756.pub3
- Schellenberg D, Menendez C, Aponte JJ, et al. Intermittent preventive treatment for Tanzanian infants: follow-up to age 2 years of a randomized, placebo-controlled trial. Lancet 2005;365:1481-3
- Chandramohan D, Webster J, Smith L, et al. Is the Expanded programme on immunisation the most appropriate delivery system for intermittent preventive treatment of malaria in West Africa? Trop Med Int Health 2007;12:743-50
- Chinbuah AM, Gyapong JO, Pagnoni F, et al. Feasibility and acceptability of the use of artemether-lumefantrine in the home management of uncomplicated malaria in children 6–59 months old in Ghana. Trop Med Int Health 2006;11:1003-16
- D'Alessandro U, Talisuna A, Boelaert M. Should artemisinin-based combination treatment be used in the home-based management of malaria? Trop Med Int Health 2005;10:1-2
- Thang ND, Erhart A, Hung LX, et al. Rapid decrease of malaria morbidity following the introduction of community-based monitoring in a rural area of central Vietnam. Malar J 2009;8:3
- Okanurak K, Ruebush TK. Village-based diagnosis and treatment of malaria. Acta Trop 1996;61:157-67
- Bell D, Go R, Miguel C, et al. Unequal treatment access and malaria risk in a community-based intervention program in the Philippines. Southeast Asian J Trop Med Public Health 2005;36:578-86
- Yeung S, Van DW, Socheat D, et al. Access to artemisinin combination therapy for malaria in remote areas of Cambodia. Malar J 2008;7:96
- Yeung S, Van DW, Socheat D, et al. Cost of increasing access to artemisinin combination therapy: the Cambodian experience. Malar J 2008;7:84
- Hopkins H, Talisuna A, Whitty CJM, et al. Impact of home-based management of malaria on health outcomes in Africa: a systematic review of the evidence. Malar J 2007;6:134
- Spencer HC, Kaseje DC, Collins WE, et al. Community based malaria control in Saradidi, Kenya: description of the programme and impact on parasitaemia rates and antimalarial antibodies. Ann Trop Med Parasitol 1987;81(Suppl 1):13-23
- Greenwood BM, Greenwood AM, Bradley AK, et al. Comparison of two strategies for control of malaria within a primary health care programme in the Gambia. Lancet 1988;1:1121-7
- Delacollette C, Van der Stuyft P, Molima K. Using community health workers for malaria control: experience in Zaire. Bull World Health Organ 1996;74:423-30
- Pagnoni F, Convelbo N, Tiendrebeogo J, et al. A community-based programme to provide prompt and adequate treatment of presumptive malaria in children. Trans R Soc Trop Med Hyg 1997;91:512-7
- Kidane G, Morrow RH. Teaching mothers to provide home treatment of malaria in Tigray, Ethiopia: a randomised trial. Lancet 2000;356:550-5
- Sirima SB, Konate A, Tiono AB, et al. Early treatment of childhood fevers with pre-packaged antimalarial drugs in the home reduces severe malaria morbidity in Burkina Faso. Trop Med Int Health 2003;8:133-9
- Ajayi IO, Browne EN, Bateganya F, et al. Effectiveness of artemisinin-based combination therapy used in the context of home management of malaria: a report from three study sites in sub-Saharan Africa. Malar J 2008;7:190
- Boni MF, Smith DL, Laxminarayan R. Benefits of using multiple first-line therapies against malaria. Proc Natl Acad Sci USA 2008;105:14216-21
- Reyburn H, Mbatia R, Drakeley C, et al. Overdiagnosis of malaria in patients with severe febrile illness in Tanzania: a prospective study. BMJ 2004;329:1212-15
- WHO Special Programme for Research and Training in Tropical Diseases. Lessons learned in home management of malaria: Implementation research in four African countries. Geneva: WHO/TDR, 2007
- Roll Back Malaria Partnership. The Global Malaria Action Plan, for a malaria-free world. The Roll Back Malaria Partnership, Geneva, 2008
- Greenwood BM, Fidock DA, Kyle DE, et al. Malaria: progress, perils, and prospects for eradication. J Clin Invest 2008;118:1266-1276
- Noedl H, Se Y, Schaecher K, et al. Evidence of artemisinin-resistant malaria in Western Cambodia. N Engl J Med 2008;359:2619-20
- WHO. Global malaria control and elimination: report of a meeting on containment of artemisinin tolerance, 19 January 2008, Geneva, Switzerland
- WHO. The Africa Malaria report 2006. Regional Offices for Africa and Eastern Mediterranean. Geneva: WHO, 2006
- Wasunna B, Zurovac D, Goodman CA, et al. Why don't health workers prescribe ACT? A qualitative study of factors affecting the prescription of artemether-lumefantrine. Malar J 2008;7:29
- Newton PN, McGready R, Fernandez F, et al. Manslaughter by Fake Artesunate in Asia—Will Africa Be Next? PLos Med 2006;3:e197